Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.

已完结 10 由 Aixuexi 发布于 2026/9/30 11:57:17

DOI:10.1016/s0140-6736(26)00602-1
作者：Nicoletta Colombo,Emese Zsiros,Gabriella Parma,Eliana Rulli,Alexandra Sebastianelli,Mariusz Bidzinski,Carlos Gallardo,Emad Matanes,Kosei Hasegawa,Fatih Kose,Manuel Magallanes-Maciel,Rebecca A Herberts
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BACKGROUND Epithelial ovarian cancer frequently recurs and becomes resistant to platinum chemotherapy. We investigated whether adding pembrolizumab to weekly paclitaxel, with or without bev

应助信息

12小时前

yan80

02f7ce15bc8411f1a02834735aa3bc31.pdf 已采纳

12小时前

Book学术机器人

2026/9/30 11:57:17 未找到该文献，机器人已退出，请等待人工下载

2026/9/30 11:57:17 Book学术AI机器人收到请求，开始寻找文献

2026/9/30 11:57:17 已向机器人发送请求

12小时前

Aixuexi 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierLigand engineering enhances Co-MOF/GF anode electrochemical degradation of atrazine.